文献速递前列腺癌

80-89岁老年男性局限性前列腺癌:基于人群登记的研究发现

Localised prostate cancer in elderly men aged 80-89 years, findings from a population-based registry.
PubMed 文献 · BJU Int · 2018-01-01

该回顾性研究基于南澳大利亚前列腺癌临床结局协作组数据,比较80-89岁与70-79岁局限性前列腺癌患者的疾病特征和前列腺癌特异性死亡率。80-89岁组Gleason评分和PSA更高,接受根治性治疗的可能性更低,但两组前列腺癌死亡比例相似,支持对老年患者进行个体化管理。

要点

  • 80-89岁组Gleason评分和PSA值高于70-79岁组,均P<0.001。
  • 80-89岁组接受根治性治疗的几率显著更低(OR 0.12,95%CI 0.09-0.16)。
  • 两组前列腺癌死亡比例相似,支持个体化治疗决策。

核心结论

  • 80-89岁与70-79岁局限性前列腺癌患者的前列腺癌死亡比例相似。
  • 研究结果支持对老年局限性前列腺癌患者进行仔细筛选的个体化管理。

研究设计与样本

  • 回顾性研究,数据来自南澳大利亚前列腺癌临床结局协作组(SA-PCCOC)。
  • 采用倾向性评分匹配和竞争风险Fine and Grey回归评估治疗机会及对PCSM的治疗效果。

主要发现

  • 80-89岁组Gleason评分和PSA值均高于70-79岁组(均P<0.001)。
  • 80-89岁组接受根治性治疗的可能性更低(OR 0.12,95%CI 0.09-0.16;P<0.001)。
  • 80-89岁组263例死亡中73例(28%)归因于前列腺癌,70-79岁组310例死亡中97例(31%)归因于前列腺癌。
  • 两组合格接受根治性治疗的患者前列腺癌特异性死亡风险均降低。

临床怎么用

  • 对80-89岁局限性前列腺癌患者应结合健康状况和肿瘤特征进行个体化治疗决策。
  • 不应仅凭年龄排除根治性治疗,但需仔细筛选合适患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the rate of prostate cancer-specific mortality (PCSM) and disease characteristics in patients diagnosed with localised prostate cancer at age 80-89 years in comparison with men diagnosed at age 70-79 years. PATIENTS AND METHODS: This is a retrospective study of data from the South Australian Prostate Cancer Clinical Outcomes Collaborative (SA-PCCOC). Included were men diagnosed between 2005 and 2014, aged ≥70 years with no evidence of metastatic disease at presentation. Propensity score matching and competing risk Fine and Grey regression were used to assess the chance of treatment (curative vs non-curative) and treatment effect on PCSM. RESULTS: Of the 1 951 eligible patients, 1 428 (76%) were aged 70-79 years and 460 (24%) were aged 80-89 years at diagnosis, with a median (interquartile range) age of 74 (72-76) and 83 (81-85) years, respectively. The 80-89 years group had higher Gleason scores and Prostate Specific Antigen (PSA) values (all P < 0.001) in comparison with the younger group. The 80-89 years group were less likely to be treated with curative treatment (odds ratio 0.12, 95% confidence interval 0.09-0.16; P < 0.001). The proportion of deaths attributable to prostate cancer was similar in both groups: 73 of 263 deaths (28%) in the 80-89 years group vs 97 of 310 deaths (31%) in the 70-79 years group. The risk of PCSM in individuals treated with curative intent was reduced in both groups. CONCLUSIONS: The proportion of prostate cancer deaths was similar in both groups. These findings support carefully selected individualised management of elderly patients diagnosed with localised prostate cancer.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Vatandoust S, Kichenadasse G, O'Callaghan M, et al. Localised prostate cancer in elderly men aged 80-89 years, findings from a population-based registry. BJU Int. 2018. PMID: 29603585. doi:10.1111/bju.14228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。